Pharma major, Ajanta Pharma, announced that the company has launched Eletriptan Hydrobromide Tablets in the US market through its wholly-owned subsidiary Ajanta Pharma USA Inc.
The product was launched in two strengths, 20 mg and 40 mg tablets. The drug is a bioequivalent generic version of Relpax 1 Tablets. It is used to treat migraines.
Meanwhile, the stock was trading up by 0.37% at Rs 1,197 per share on BSE at 1105 hours. The stock attracted a total traded volume of 2,09,575 shares and traded value of Rs 2,534.31 lakh on NSE at 1107 hours.
The drug is part of an ever growing portfolio of products that Ajanta has developed for the US market. In total, the company has 35 Abbreviated New Drug Applications (ANDAs) of which it has 19 final ANDA approvals, 2 tentative approvals, and 14 ANDAs under review with US FDA. So far it has launched 14 products in the US market.
The company’s consolidated revenue for the Q1FY18 remained flat at Rs 473 crore as against Rs 476 crore in corresponding quarter of last year. The PAT for the quarter came in at Rs 94.8 crore, yoy decline of 20.7%.
Capitalstars Financial Research Private Limited is a research house and an investment advisory carrying out operations in the Indian Equities and Commodity market.We also provide free trial to our client.Join our services and trade with us.
Get more details here:-
* Investment & Trading in securities market is always subjected to market risks, past performance is not a guarantee of future performance.
0 comments:
Post a Comment